by Tom Santanna
Over the last year, the Pennsylvania Department of Health has implemented the legislative Act 16 of 2016, allowing for a medical cannabis program, without any major delays. Regulations have been drafted and published, and the first round of licenses for growing, processing and distributing medical cannabis have been awarded.
Seventeen qualifying conditions allow patients to receive medical cannabis therapy, including HIV/AIDS, Parkinson’s disease, multiple sclerosis, spinal or neurological indication of spasticity, inflammatory bowel, Huntington’s disease, Crohn’s disease, post-traumatic stress disorder, intractable seizures, glaucoma, autism, sickle cell anemia, neuropathy and pain, defined in the statute as “severe chronic or intractable pain of neuropathic origin or severe chronic or intractable pain in which conventional therapeutic intervention and opiate therapy is contraindicated or ineffective. Continue reading